Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Banyu Confirms Efficacy, Safety of Simvastatin in Clinical Trail
January 15, 2001
- CAPC's Executive Committee Recommends Approval of 16 Active Ingredients
January 15, 2001
- medical facilities & nursing care news on brief
January 15, 2001
- REGULATORY NEWS IN BRIEF -2-
January 15, 2001
- Cooperation with Companies Is Essential: RIKEN Researcher
January 15, 2001
- Sales of Takeda's Blopress Skyrocket: Top 100 Products Ranking
January 15, 2001
- Tissue Engineering Chair Donated by BCS at Tokai Univ.
January 15, 2001
- NHI Price System Reform Shelved in Japan: US ITC Report
January 15, 2001
- abbreviation
January 15, 2001
- Growth of Morphine Consumption Slows Down
January 15, 2001
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
- Changing OTC Business Strategy, Priority Shifts to Volume Retailers
January 15, 2001
- Welfide Transfers Infusion Fluid Business to Otsuka Pharmaceutical Factory, Inc
January 15, 2001
- OTC news on brief
January 15, 2001
- Suntory, Taisho to Codevelop SUN N8075 for Cerebral Infarction
January 15, 2001
- Sankyo, Mochida Tie Up with Riken
January 15, 2001
- Tanabe Licenses Out TR-14035 to SmithKline Beecham
January 15, 2001
- Asahi Chemical Invests US$9 Mil in Circe Biomedical
January 15, 2001
- Sumitomo Ties Up With Gene Logic
January 15, 2001
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…